Archive for the 'Sarcomatoid' Category
Less common than epithelioid mesothelioma, only 7% to 20% of mesothelioma are sarcomatoid. Often called the “wild” type because of it’s unpredictable nature.
October 17th, 2006. Spindle cell tumors of the pleura: differential diagnosis
Desmoplastic malignant mesothelioma is a fibrous sarcomatoid variant of malignant mesothelioma, and is occasionally mistaken for chronic fibrous pleurisy. Here, we review morphological, clinical, histological, immunohistochemical, ultrastructural, and molecular methods that aid in the diagnosis of spindle cell tumors of the pleura, and we provide specific examples of patients in which this multi-modal approach proved to be helpful.
October 7th, 2006. Sarcomatous pleural mesothelioma metastatic to left ventricular endocardium
Abstract A 71-year-old man, a cigarette smoker with long-term asbestos exposure, developed multifocal malignant sarcomatous pleural mesothelioma that metastasized to the left ventricular endocardium without invading pericardium, myocardium, or the contiguous pulmonary vein. This is the first reported case of malignant pleural mesothelioma to metastasize in such a manner.
September 6th, 2006. Heterogeneous nuclear ribonucleoprotein B1 expression in malignant mesothelioma
This protein may regulate proliferation linked with differentiation toward epithelioid morphology in mesothelial cells. Expression of the protein may be a prognostic indicator for patents with malignant mesothelioma.
September 6th, 2006. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress
This offers a possible mechanism of action of selenite treatment. Our findings suggest that selenite is a promising new drug for the treatment of malignant mesothelioma.
July 25th, 2006. Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors
The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epithelioid, Full Archive, Peritoneal (Abdominal Mesothelioma), Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 5th, 2006. Epithelioid and sarcomatoid malignant pleural mesothelioma in endoscopic gastric biopsies: A diagnostic pitfall
We herein present the first two cases of MM (one each of EM and SM) of the pleura, presenting in endoscopic gastric biopsies as small polypoid lesions and poorly healing ulcers 30 and 35 months after the initial diagnosis of pleural MM, respectively. The major differential diagnoses encompass primary or metastatic adenocarcinoma in case one and cytokeratin-positive (KIT negative!) GI stromal tumors (GISTs) and sarcomatoid carcinoma in case two, as well as other rare entities.
June 21st, 2006. D2-40: A Reliable Marker in the Diagnosis of Pleural Mesothelioma
Conclusions: We regard D2-40 as a valid marker in the differential diagnosis of epithelioid mesotheliomas versus pulmonary adenocarcinomas. However, this marker may not properly label sarcomatoid mesotheliomas or distinguish them from reactive pleural lesions.
June 9th, 2006. Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma
For pro-apoptotic proteins, loss of expression was recorded as follows: Bad 25% (14/54), Bak 24% (13/54), Bax 42% (23/54), Bid 37% (20/54), Bim 18% (10/54). Statistically significant differences between epithelial and sarcomatoid tumours were observed for Bid (p.
June 8th, 2006. Pathology of primary tumors and pseudotumors of the pleura
Histological types include mesothelioma, epitheliod, biphasic or sarcomatoid tumors as well as primary lymphoma and mesenchymatous tumors which include solitary fibrous tumor, epithelioid hemangioendothelioma and angiosarcoma and synovialosarcoma. We detail here the new WHO classification 2004 explaining the different entities, excluding metastatic tumors which are the most frequent tumors of the pleura.
April 25th, 2006. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients
To characterize the biological differences between Y-MESO-8A and Y-MESO-8D, we carried out cDNA microarray analysis and detected genes that were differentially expressed in these two cell lines. Thus, our new MPM cell lines seem to be useful as new models for studying various aspects of the biology of human MPM as well as materials for the development of future therapies.
Posted in Biphasic or Mixed, Epithelioid, Full Archive, Gene Therapy, New & Novel, Pleural, Sarcomatoid, SV40, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 2nd, 2006. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura
Conclusions: The results show that malignant mesotheliomas have a lower expression of claudins 1, 3, 4, 5, and 7 than adenocarcinomas, and their expression could thus be used as an adjunct in differential diagnosis between the two. The difference was most evident for claudins 3 and 4, which were nearly as good as calretinin in mesothelioma detection. Sarcomatoid and biphasic mesotheliomas showed expression of these claudins only occasionally, which could be due to or contribute to their less epithelial appearance.
February 8th, 2006. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells
PSI seemed to decrease mesothelioma viability by inducing apoptosis, as verified by cell morphology, Western blotting analysis of caspase 3 cleavage, and flow-cytometric analysis. In conclusion, PSI, a representative agent that reduces viability and induces apoptosis of mesothelioma cells, might be useful in the treatment of patients with mesothelioma, especially of epithelioid phenotype.
January 11th, 2006. Mesothelioma with rhabdoid features: an ultrastructural and immunohistochemical study of 10 cases
It is important for pathologists to be aware that mesotheliomas can present rhabdoid features, not only because they can be confused with other malignancies that can exhibit a similar morphology, but also because of their apparently unusually aggressive behavior. The value of immunohistochemistry and electron microscopy in the differential diagnosis of these tumors is discussed.
December 23rd, 2005. Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration–a case report
FNAC is accurate and efficient, in conjugation with clinical history, and it also prevents surgical biopsy in the diagnosis of metastatic subcutaneous lesion. To our knowledge, this is the first case, reported till date, in which the sarcomatoid mesothelioma metastasized to the subcutaneous tissue and was diagnosed by fine needle aspiration cytology (FNAC).
November 21st, 2005. Cisplatin-Induced GADD34 Upregulation Potentiates Oncolytic Viral Therapy in the Treatment of Malignant Pleural Mesothelioma
Conclusion: Cisplatin-induced GADD34 expression selectively enhanced the cytotoxicity of the gamma(1)34.5-deficient oncolytic virus, NV1066. This provides a cellular basis for combination therapy with cisplatin and NV1066 to treat MPM and achieve synergistic efficacy, while minimizing dosage and toxicity.
Posted in Biphasic or Mixed, Chemotherapy, Cisplatin (Platinol ®), Epithelioid, Full Archive, Gene Therapy, New & Novel, Sarcomatoid, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 1st, 2005. Recognition of histopathologic patterns of diffuse malignant mesothelioma in differential diagnosis of pleural biopsies
Conclusion: Pathologists should be aware of the varied histologic patterns of diffuse malignant mesothelioma when evaluating pleural biopsies.
May 1st, 2005. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis
The varied morphology of peritoneal malignant mesotheliomas may raise a broad differential diagnosis, but in most cases the resemblance to other tumors is limited. Histochemistry, immunohistochemistry, and electron microscopy may provide important aid, particularly when tissue is limited, but should be needed only occasionally.
|
|  |
